GSK
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.06 | 10 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×1.17 | 5 |
| preclinical | ×0.72 | 5 |
| approved | ×1.14 | 3 |
Strategy profile
Based on 15 disclosed transactions, GSK concentrates its licensing activity in Oncology, Other, and Cardiovascular. GSK pays a 1.03x premium over market median, with the strongest premiums in Oncology (1.06x). Their most common deal structure is License, with an average disclosed value of $2.7B. Most recent activity: 2026.
Premium by therapeutic area
How GSK pays relative to peer medians in each TA
Pipeline coverage & gaps
GSK has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 8 | $88M | $1.1B |
| Acquisition | 6 | $3.7B | $3.2B |
| Option | 1 | $500M | $12.5B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | HMPL-A830 | Hutchmed | — | unknown | $110M | $1.4B |
| 2026 | Cancer drug (undisclosed name) | Chimagen Biosciences | cancer | unknown | — | $750M |
| 2026 | HMPL-A830 | Hutchmed | — | phase_1 | $110M | $1.3B |
| 2026 | Trispecific T-cell engager | Chimagen | T-cell lymphoma | preclinical | — | $750M |
| 2026 | HMPL-A830 | Hutchison China MediTech | — | phase_1 | $110M | $1.3B |
| 2026 | HMPL-A830 | HUTCHMED | colorectal, pancreatic and lung cancer | phase_1 | $110M | $1.3B |
| 2026 | HMPL-A830 | Hutchison China MediTech | — | phase_1 | $110M | $1.3B |
| 2026 | Nuvalent pipeline (targeted kinase inhibitors for NSCLC) | Nuvalent, Inc. | non-small cell lung cancer | phase_3 | $10.6B | $10.6B |
| 2026 | HRS-9821 | Jiangsu Hengrui | COPD | unknown | $500M | $12.5B |
| 2026 | siRNA obesity program | Siran Biotechnology | obesity and metabolic disease | preclinical | $1.0B | $1.0B |
| 2026 | JNJ-3989 | Arrowhead/Janssen | hepatitis B | unknown | — | $3.7B |
| 2026 | — | Frontier Biotechnologies Inc. | autoimmune | unknown | $40M | $1.0B |
| 2026 | HS235 | 35Pharma | pulmonary arterial hypertension | phase_1 | $950M | $950M |
| 2026 | ozureprubart (zelorigotab / RPT193) and full RAPT Therapeutics pipeline | RAPT Therapeutics | severe asthma | phase_2 | $2.2B | $2.2B |
| 2026 | bepirovirsen | Ionis Pharmaceuticals | chronic hepatitis B | phase_3 | $25M | $512M |
How this is computed
For each GSK deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 15 disclosed deal premiums vs. peer medians. Raw premium 1.035, clamped to [0.7, 1.5].